Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High density lipoprotein measurement
|
1440 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.800 | 1.000 | 4 | 2010 | 2019 | |||||
Low density lipoprotein cholesterol measurement
|
1142 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.800 | 1.000 | 3 | 2012 | 2019 | |||||
Colorectal Carcinoma
|
1962 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.800 | 1.000 | 2 | 2014 | 2019 | |||||
Serum total cholesterol measurement
|
1243 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.800 | 1.000 | 2 | 2012 | 2017 | |||||
Triglycerides measurement
|
1418 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.800 | 1.000 | 2 | 2012 | 2019 | |||||
Metabolic Syndrome X
|
591 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.800 | 1.000 | 1 | 2010 | 2010 | |||||
Serum albumin measurement
|
3282 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 2 | 2012 | 2013 | |||||
Serum HDL cholesterol measurement
|
679 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 2 | 2012 | 2012 | |||||
Adenocarcinoma of large intestine
|
432 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Chronic Kidney Diseases
|
306 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
374 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
|
370 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
|
373 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
|
368 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Colorectal Neoplasms
|
609 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Inflammatory Bowel Diseases
|
605 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2015 | 2015 | |||||
Kidney Failure, Chronic
|
425 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2018 | 2018 | |||||
Malignant neoplasm of large intestine
|
375 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Malignant tumor of colon
|
688 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Phosphatidylcholine measurement
|
19 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Phospholipid measurement
|
306 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||
Serum LDL cholesterol measurement
|
555 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||
Congestive heart failure
|
165 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Neoplasms
|
1644 | 0.752 | 0.240 | 11 | 61830500 | intron variant | A/G | snv | 0.31 | 0.010 | 1.000 | 1 | 2017 | 2017 |